ZIOPHARM Commences Oral Indibulin Phase I/II Trial In Breast Cancer -- At Memorial Sl
 

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of oral indibulin (Zybulin? or ZIO-301) in the treatment of metastatic breast cancer...

More...